Guerbet Announces Launch and Dosing of Elucirem MRI Contrast

Monday, February 13, 2023

Guerbet announced the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022.

According to the company, this highly stable macrocyclic gadolinium-based contrast agent (GBCA) has the highest relativity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.

Elucirem tackles practitioners' concerns about gadolinium exposure because it only requires half the gadolinium dosage of conventional non-specific GBCAs. At the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, the first dose was administered.

Use the injection Elucirem™ (Gadopiclenol) to find tumours with abnormal vascularity in the body's central nervous system (brain, vertebrae, and associated tissues) (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

GBCAs improve the contrast between lesions and surrounding tissues by accelerating the relaxation of protons thanks to interaction with gadolinium atoms.  
Gadopiclenol, the active drug substance of Elucirem™, has been designed to enable twice as much interaction, resulting in the highest relaxivity among all non-specific GBCAs. This allows use at half the conventional gadolinium dose to reveal high-quality images.

Elucirem is manufactured by Liebel-Flarsheim™ Company LLC, a Guerbet Group company, in Raleigh, North Carolina.

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO SummitHealthcare CMO Summit